OCULAR THERAPEUTIX INC's ticker is OCUL and the CUSIP is 67576A100. A total of 109 filers reported holding OCULAR THERAPEUTIX INC in Q3 2020. The put-call ratio across all filers is 1.19 and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $189,543 | -85.7% | 60,364 | -76.5% | 0.00% | – |
| Q2 2023 | $1,327,503 | +115.2% | 257,268 | +119.8% | 0.00% | – |
| Q1 2023 | $616,832 | +694.7% | 117,046 | +323.7% | 0.00% | – |
| Q4 2022 | $77,620 | -17.4% | 27,623 | +21.9% | 0.00% | – |
| Q3 2022 | $94,000 | -50.3% | 22,658 | -51.7% | 0.00% | – |
| Q2 2022 | $189,000 | -59.4% | 46,944 | -29.5% | 0.00% | – |
| Q4 2021 | $465,000 | -68.3% | 66,575 | -54.6% | 0.00% | – |
| Q3 2021 | $1,465,000 | -35.2% | 146,557 | -8.1% | 0.00% | – |
| Q2 2021 | $2,260,000 | +233.8% | 159,395 | +286.4% | 0.00% | – |
| Q1 2021 | $677,000 | -37.9% | 41,246 | -21.7% | 0.00% | – |
| Q4 2020 | $1,090,000 | +376.0% | 52,653 | +74.8% | 0.00% | – |
| Q3 2020 | $229,000 | -79.3% | 30,126 | -77.3% | 0.00% | -100.0% |
| Q2 2020 | $1,107,000 | +412.5% | 132,900 | +205.0% | 0.00% | – |
| Q1 2020 | $216,000 | +137.4% | 43,579 | +223.1% | 0.00% | – |
| Q2 2018 | $91,000 | – | 13,489 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SUMMER ROAD LLC | 5,618,424 | $46,801,000 | 100.00% |
| Opaleye Management Inc. | 5,984,200 | $49,848,000 | 10.07% |
| DELTEC ASSET MANAGEMENT LLC | 2,330,267 | $19,411,000 | 4.06% |
| Corriente Advisors, LLC | 720,000 | $5,998,000 | 3.89% |
| Versant Venture Management, LLC | 2,215,384 | $18,454,145,000 | 2.65% |
| SV Health Investors, LLC | 312,068 | $2,600,000 | 1.80% |
| Ikarian Capital, LLC | 2,055,977 | $17,126,000 | 1.36% |
| EAM Global Investors LLC | 265,316 | $2,210,000 | 0.99% |
| EAM Investors, LLC | 346,075 | $2,883,000 | 0.64% |
| RA Capital Management | 2,727,272 | $22,718,000 | 0.44% |